Long Term Update Confirms Risk Reduction In Heart Failure Hospitalization

(RTTNews) - LivaNova Plc. (LIVN) announced long term results from the RESPOND-CRT clinical trial after an 18 month follow-up period.

Longer term results, after a complete 18 months patient follow-up, confirmed the significant risk reduction in heart failure hospitalization on the overall population enrolled in the study. Additionally, in subgroups of patients with atrial fibrillation and renal dysfunctions, a 48% and 41% risk reduction in cardiovascular death or hospitalization was observed with SonR, respectively.

The results were presented by the principal investigator, Prof. Josep Brugada, at an oral Clinical Trial Update session during the annual European Society of Cardiology meeting.

The RESPOND-CRT trial was designed to investigate the clinical efficacy and safety of device-based optimization using LivaNova's proprietary SonR cardiac contractility sensor technology in patients with advanced heart failure.

Previously, on May 5, 2016, LivaNova announced the RESPOND-CRT one-year results at the annual Heart Rhythm Society or HRS and subsequently published a press release. The one-year data showed that the study met its primary safety and efficacy end points and demonstrated that SonR was associated with a 35% risk reduction in heart failure hospitalization.

Automatic optimization with SonR was compared to manual echocardiography guided optimization. The proprietary SonR optimization system allows for cardiac resynchronization therapy to be continuously adapted to the needs of each patient, thus delivering an individualized therapy.